Thyroid Ultrasound and Fine Needle Aspiration Biopsy

Thyroid ultrasound and fine needle aspiration (FNA) biopsy are the two foundational diagnostic tools used to evaluate thyroid nodules — focal abnormalities within the thyroid gland that affect an estimated 19–35% of the general population when assessed by high-resolution ultrasound, according to the American Thyroid Association (ATA). This page covers how each procedure works, the clinical scenarios that prompt their use, and the structured decision frameworks that guide whether a nodule requires biopsy. Understanding these tools is essential to the broader endocrine evaluation process described across endocrinologyauthority.com.

Definition and Scope

Thyroid ultrasound is a non-invasive imaging modality that uses high-frequency sound waves — typically in the 7.5–15 MHz range — to produce real-time images of the thyroid gland, adjacent lymph nodes, and surrounding neck structures. It produces no ionizing radiation and is considered the first-line imaging tool for thyroid evaluation by the American College of Radiology (ACR) and the ATA.

Fine needle aspiration biopsy is a minimally invasive sampling procedure in which a thin needle (typically 25–27 gauge) is inserted into a thyroid nodule — almost always under ultrasound guidance — to extract cells for cytopathological analysis. The combination of ultrasound guidance with FNA, often written as US-FNA, has a reported sensitivity of approximately 83–98% and specificity of approximately 70–92% for detecting malignancy, as published in data reviewed by the National Cancer Institute (NCI).

These procedures sit within the broader landscape of thyroid function tests and imaging-based diagnostics. The scope of thyroid ultrasound extends beyond nodule detection: it is also used to monitor nodule growth over time, assess lymph node involvement in confirmed thyroid cancer, and guide percutaneous interventions such as ethanol ablation.

The regulatory context for endocrinology in the United States places thyroid ultrasound under standard medical imaging regulations, with quality standards governed by the ACR's Thyroid Ultrasound Accreditation Program and equipment performance standards defined under 21 CFR Part 892 (FDA medical device regulations).

How It Works

Thyroid Ultrasound — Procedural Steps:

  1. The patient lies supine with the neck extended over a pillow or cushion to expose the anterior neck.
  2. A transducer coated with acoustic gel is placed on the skin surface overlying the thyroid.
  3. Images are acquired in transverse and longitudinal planes for both thyroid lobes and the isthmus.
  4. Each nodule is characterized by size (three dimensions in centimeters), echogenicity (hypoechoic, isoechoic, hyperechoic, or anechoic), composition (solid, cystic, or mixed), margins, shape, and the presence of calcifications.
  5. Lymph nodes in the central and lateral neck compartments are assessed.

The ACR's Thyroid Imaging Reporting and Data System (TI-RADS), published in 2017, assigns points to ultrasound features across five categories — composition, echogenicity, shape, margin, and echogenic foci — generating a TI-RADS level from TR1 (benign) to TR5 (highly suspicious) that directly informs biopsy thresholds.

Fine Needle Aspiration — Procedural Steps:

  1. The target nodule is identified and localized under real-time ultrasound.
  2. The skin is cleansed; local anesthesia with lidocaine may be applied.
  3. A 25-gauge needle attached to a syringe is advanced into the nodule under continuous ultrasound visualization.
  4. Cells are aspirated using either suction (aspiration technique) or a to-and-fro capillary action method (non-aspiration technique).
  5. Typically 2–4 passes are made to ensure adequate cellularity.
  6. Specimens are smeared onto glass slides or placed in liquid medium for cytopathological evaluation.

Cytopathology results are reported using the Bethesda System for Reporting Thyroid Cytopathology, a standardized six-category classification published by the National Cancer Institute that assigns malignancy risk to each diagnostic category.

Common Scenarios

Thyroid ultrasound is indicated across a defined set of clinical presentations. The most frequent include:

FNA biopsy is triggered when ultrasound features and nodule size cross defined thresholds. Under the ATA's 2015 guidelines, nodules with high-suspicion features warrant FNA at ≥1 cm, while very low-suspicion (spongiform or cystic) nodules may not require biopsy regardless of size.

Decision Boundaries

The decision to proceed from ultrasound to FNA is governed by two major frameworks in active clinical use: ACR TI-RADS and the ATA 2015 guidelines. These systems agree on principles but differ in specific size thresholds.

ACR TI-RADS Size Thresholds for FNA:

TI-RADS Level Feature Description FNA Threshold
TR1 Benign No biopsy
TR2 Not suspicious No biopsy
TR3 Mildly suspicious ≥ 2.5 cm
TR4 Moderately suspicious ≥ 1.5 cm
TR5 Highly suspicious ≥ 1.0 cm

After FNA, the Bethesda System assigns results to one of six categories:

(Risk ranges sourced from the Bethesda System for Reporting Thyroid Cytopathology, 3rd edition, NCI.)

Bethesda III and IV results frequently prompt molecular testing — such as Afirma Gene Sequencing Classifier or ThyroSeq v3 — to refine surgical decision-making, though molecular testing falls under additional clinical and payer authorization frameworks.

Patients with non-diagnostic results (Bethesda I) on two separate FNA attempts may proceed to surgical excision for definitive histopathologic diagnosis. Nodules classified as Bethesda II with no high-risk features enter a surveillance interval of 12–24 months between ultrasounds, consistent with ATA recommendations.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)